Metabolon’s Metabolomic Platform and Services Cited in More Than 3,000 Peer-Reviewed Articles across Life Sciences, Pharmaceutical/Biotech, and Applied Sciences

Posted In: Company News
metabolon cited 3000 articles

MORRISVILLE, N.C. – March 29, 2023 – Metabolon, Inc., the global leader in providing metabolomics solutions that advance a wide variety of research, diagnostic, therapeutic development, and precision medicine applications, today announced their metabolomics platform outputs and related services have been cited in more than 3,000 peer-reviewed journals. For more than 20 years, Metabolon has been focused on developing and refining its platform to enable the utility of metabolomics in all areas of life sciences research. The scientific insights supported by Metabolon’s high-quality metabolomic outputs have allowed the company to reach this historic milestone.

Publications referencing Metabolon, its platform and results have appeared in world-renowned, high-impact journals such as Nature, Nature Medicine, Nature Genetics, Cell, Proceedings of the National Academy of Sciences (PNAS), and many others, demonstrating the dramatic increase in awareness and recognition of the importance of metabolomics in research. Metabolon continues to support active collaboration across scientific disciplines, enabling continuous growth and adoption among the life sciences and scientific innovation communities. Metabolon’s contribution to scientific studies was cited in its 1,000th peer-reviewed article in 2016 and has been increasingly cited since, with nearly 75 in January and February 2023 on topics ranging from COVID-19 to inflammation.  As a result, there are now more than 3,000 publications citing Metabolon’s contributions, and the number continues to grow.

“Metabolon continues to actively engage the scientific communities to highlight the importance of metabolomics to further basic science, clinical research, and medicine, as well as broaden our understanding of wellness and human health. Metabolomics is unique in providing the best link to functional and phenotypic attributes, that help translate biology from discovery through clinical development and is complementarity to gene-based applications in the pharmaceutical industry,” said Rohan (Ro) Hastie, CEO at Metabolon. “We’re dedicated to providing this important building block to advance research across disease states and ultimately revolutionize drug development.”

“The citations of Metabolon’s metabolomics platform outputs and services across this breadth of scientific disciplines highlights the impact of metabolomics in these fields of study,” said Ranga Sarangarajan, Chief Scientific Officer at Metabolon. “This milestone shows how we are transforming the way scientists approach the incorporation of metabolomics in all applicable areas of science, including life science, health, and wellness research. Metabolon is dedicated to providing high-quality metabolomics outputs to various disciplines, as well as the development of tools and capabilities for advanced statistical analysis, multi-omics data integration, and the use of machine learning and artificial intelligence analytics.”

Contact Us

Talk with an expert

Request a quote for our services, get more information on sample types and handling procedures, request a letter of support, or submit a question about how metabolomics can advance your research.

Corporate Headquarters

617 Davis Drive, Suite 100
Morrisville, NC 27560

Mailing Address:
P.O. Box 110407
Research Triangle Park, NC 27709

+1 (919) 572-1711

+1 (919) 572-1721

International Headquarters

Metabolon GmbH

Zeppelinstraße 3
85399 Hallbergmoos